About BioGenesis

Who We Are

BioGenesis is a leading biotechnology company dedicated to advancing nucleic acid therapeutics and protein engineering. Founded in 2018 and headquartered in Shanghai Zhangjiang Hi-Tech Park, we have grown from a small research team to a comprehensive biopharmaceutical service provider.

Our Mission

To accelerate the development of nucleic acid drugs and protein therapeutics through innovative technology platforms, enabling breakthrough treatments for patients worldwide.

Our Vision

To become the most trusted partner for biopharmaceutical companies and research institutions in nucleic acid and protein engineering, driving the next generation of precision medicine.

Core Values

  • Scientific Excellence: Rigorous research methodology and cutting-edge technology
  • Innovation: Continuous investment in R&D and novel platform development
  • Collaboration: Open partnerships with academia and industry
  • Quality: GMP-compliant manufacturing with comprehensive quality control
  • Integrity: Transparent communication and ethical business practices

Technology Platforms

Our integrated technology platforms span the full spectrum of nucleic acid and protein engineering:

mRNA Platform

End-to-end mRNA design, optimization, and synthesis capabilities from research to GMP-grade production.

siRNA Platform

AI-powered siRNA design and high-throughput screening for efficient gene silencing.

Enzyme Platform

Premium enzyme products and custom enzyme engineering services.

Glycoengineering Platform

Advanced protein glycosylation engineering and characterization services.

Certifications & Quality

  • GMP-certified manufacturing facility
  • ISO 9001:2015 quality management system
  • ISO 13485:2016 medical device quality management

Core Team

Led by world-class scientists with decades of experience in nucleic acid therapeutics and protein engineering

WC

Dr. Wei Chen

Founder & CEO

Ph.D. in Molecular Biology from MIT. 15+ years of experience in nucleic acid therapeutics. Former Senior Scientist at Moderna.

ML

Dr. Mei Li

Chief Scientific Officer

Ph.D. in Biochemistry from Stanford. Expert in protein engineering and glycosylation biology. Published 50+ peer-reviewed papers.

JZ

Dr. Jun Zhang

VP of Technology

Ph.D. in Computational Biology from Tsinghua University. Specialist in AI-driven nucleic acid sequence optimization.

FW

Fang Wang

Director of Manufacturing

M.S. in Chemical Engineering. 12+ years in GMP manufacturing of biologics and nucleic acid products.

Our Journey

Key milestones in BioGenesis's growth and innovation

2018

Company Founded

BioGenesis was established in Shanghai with a mission to advance nucleic acid therapeutics.

2019

First mRNA Product Launch

Launched our first commercial mRNA synthesis service for research customers.

2020

Series A Funding

Closed Series A funding of $20M to expand R&D capabilities and team.

2021

siRNA Platform Launch

Introduced our AI-powered siRNA design and screening platform.

2022

GMP Facility Certified

Achieved GMP certification for our nucleic acid manufacturing facility.

2024

New R&D Center

Opened new 5,000 sqm R&D laboratory in Shanghai Zhangjiang Hi-Tech Park.

Join Us

We are always looking for talented scientists and professionals to join our team. If you are passionate about advancing biotechnology, we want to hear from you.

View Open Positions β†’